首页> 外文OA文献 >An International Survey-based Algorithm for the Pharmacologic Treatment of Chorea in Huntington’s Disease
【2h】

An International Survey-based Algorithm for the Pharmacologic Treatment of Chorea in Huntington’s Disease

机译:一种基于国际调查的亨廷顿舞蹈病舞蹈症药物治疗算法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

It is generally believed that treatments are available to manage chorea in Huntington’s disease (HD). However, lack of evidence prevents the establishment of treatment guidelines. The HD chorea research literature fails to address the indications for drug treatment, drug selection, drug dosing and side effect profiles, management of inadequate response to a single drug, and preferred drug when behavioral symptoms comorbid to chorea are present. Because there is lack of an evidence base to inform clinical decision-making, we surveyed an international group of experts to address these points. Survey results showed that patient stigma, physical injury, gait instability, work interference, and disturbed sleep were indications for a drug treatment trial. However, the experts did not agree on first choice of chorea drug, with the majority of experts in Europe favoring an antipsychotic drug (APD), and a near equal split in first choice between an APD and tetrabenazine (TBZ) among experts from North America and Australia. All experts chose an APD when comorbid psychotic or aggressive behaviors were present, or when active depression prevented the use of TBZ. However, there was agreement from all geographic regions that both APDs and TBZ were acceptable as monotherapy in other situations. Perceived efficacy and side effect profiles were similar for APDs and TBZ, except for depression as a significant side effect of TBZ. Experts used a combination of an APD and TBZ when treatment required both drugs for control of chorea and a concurrent comorbid symptom, or when severe chorea was inadequately controlled by either drug alone. The benzodiazepines (BZDs) were judged ineffective as monotherapy but useful as adjunctive therapy, particularly when chorea was exacerbated by anxiety. There was broad disagreement about the use of amantadine for chorea. Experts who had used amantadine described its benefit as small and transient. In addition to survey results, this report reviews available chorea studies, and lastly presents an algorithm for the treatment of chorea in HD which is based on expert preferences obtained through this international survey.
机译:人们普遍认为,可以利用治疗亨廷顿舞蹈病(HD)的舞蹈病的方法。但是,缺乏证据阻碍了治疗指南的建立。 HD舞蹈病研究文献未能解决药物治疗的适应症,药物选择,药物剂量和副作用情况,对单一药物反应不足的处理以及当出现与舞蹈病相伴的行为症状时首选药物的问题。由于缺乏可为临床决策提供依据的证据,我们调查了一个国际专家小组来解决这些问题。调查结果表明,患者的耻辱感,身体伤害,步态不稳,工作干扰和睡眠障碍是药物治疗试验的指征。但是,专家们并未就霍乱病药物的首选达成一致,欧洲的大多数专家都倾向于抗精神病药(APD),而北美的专家在APD和丁苯那嗪(TBZ)的选择上几乎相等。和澳大利亚。当出现合并的精神病或攻击行为,或者由于主动抑郁而无法使用TBZ时,所有专家都选择APD。但是,所有地理区域都同意,在其他情况下,APD和TBZ均可作为单一疗法。 APD和TBZ的感知功效和副作用概况相似,但抑郁症是TBZ的重要副作用。当治疗需要两种药物来控制舞蹈症和并发合并症状时,或者当仅使用这两种药物不能充分控制严重的舞蹈症时,专家会同时使用APD和TBZ。苯二氮卓类药物(BZDs)被认为不能作为单一疗法有效,但可作为辅助疗法,特别是当焦虑症使舞蹈病恶化时。关于金刚烷胺用于舞蹈治疗存在广泛的分歧。曾经使用金刚烷胺的专家将其益处描述为短暂而短暂。除调查结果外,本报告还回顾了可用的舞蹈病研究,最后提出了一种通过本次国际调查获得的专家偏好来治疗HD舞蹈病的算法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号